Stockscreener 앱 받기
76.45
0.88%
-0.68
시간 외 거래:
76.45
전일 마감가:
$77.13
열려 있는:
$76.69
하루 거래량:
2.24M
Relative Volume:
0.88
시가총액:
$10.38B
수익:
$105.82M
순이익/손실:
$-829.61M
주가수익비율:
-11.17
EPS:
-6.8429
순현금흐름:
$-548.92M
1주 성능:
-5.17%
1개월 성능:
-11.61%
6개월 성능:
+18.11%
1년 성능:
+108.37%
1일 변동 폭
$74.89
$77.17
1주일 범위
$74.89
$81.02
52주 변동 폭
$32.89
$88.31
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare CYTK vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
76.45 | 10.95B | 105.82M | -829.61M | -548.92M | -6.8429 |
VRTX
Vertex Pharmaceuticals Inc
|
470.72 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
759.24 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
830.79 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
182.45 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
313.77 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-10 | 개시 | Wells Fargo | Overweight |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-12-18 | 업그레이드 | Goldman | Neutral → Buy |
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
CYTK4910847 Bond Profile — Key Metrics - TradingView
Form 4 Cytokinetics Inc For: 27 July By Investing.com - Investing.com Canada
Cytokinetics (NASDAQ: CYTK) CEO sells 7,500 shares after option exercise - Stock Titan
Cytokinetics president & CEO Robert Blum sells $606,525 in stock By Investing.com - Investing.com Canada
Cytokinetics president & CEO Robert Blum sells $606,525 in stock - Investing.com
Cytokinetics Insider Sold Shares Worth $606,525, According to a Recent SEC Filing - Yahoo Finance
Cytokinetics Inc (CYTK) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cytokinetics Inc (CYTK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cytokinetics Inc (CYTK) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cytokinetics Inc (CYTK) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CYTK|Cytokinetics Inc|Price:80.740|Chg%:-1.180 - TradingKey
Cytokinetics Inc (CYTK) Balance Sheet - TradingKey
Cytokinetics, Incorporated Revenue Breakdown – BX:KK3A - TradingView
Cytokinetics, Incorporated Revenue Breakdown – FWB:KK3A - TradingView
Cytokinetics, Incorporated Revenue Breakdown – LS:A1W1KK - TradingView
Cytokinetics, Incorporated (CYTK) Stock Forecasts - Yahoo! Finance Canada
Cytokinetics, Incorporated (CYTK) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cytokinetics, Incorporated (CYTK) stock price, news, quote and history - Yahoo Finance UK
Cytokinetics EVP Fady Malik sells $282,065 in company stock By Investing.com - Investing.com Nigeria
Form 4 Cytokinetics Inc For: 24 July By Investing.com - Investing.com Nigeria
Cytokinetics EVP Fady Malik sells $282,065 in company stock - Investing.com
Cytokinetics Inc (CYTK) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Insider Sell Alert: Fady Malik Sells 3,500 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $282,065, According to a Recent SEC Filing - marketscreener.com
Cytokinetics to Announce Second Quarter Results on August 6, 2026 - The Manila Times
Cytokinetics Will Share Q2 Results Aug. 6, Then Host Live Call - Stock Titan
CYTK stock holds recent gains as Cytokinetics prepares next heart failure data readout - AD HOC NEWS
Cytokinetics Inc (CYTK) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cytokinetics, Incorporated (CYTK) Options Chain - Yahoo! Finance Canada
Cytokinetics: Label Expansion Can Turn MYQORZO Into An HCM Franchise (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics' Myqorzo: The Challenger Drug Poised to Reshape a Multi-Billion Dollar Heart Market - Kavout | AI
Cytokinetics CEO on the launch of its first commercial drug - Yahoo Finance
Cytokinetics stock edges higher as cardiovascular pipeline and cash position underpin outlook - Ad-hoc-news.de
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Citi Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $99 - Moomoo
Form 4 Cytokinetics Inc For: 16 July By Investing.com - Investing.com Nigeria
Cytokinetics (CYTK) director Nancy Wysenski granted 75 fully vested shares - Stock Titan
Director stock grant at Cytokinetics (CYTK) highlights equity retainer - Stock Titan
Cytokinetics (CYTK) awards 151-share fully vested grant to director - Stock Titan
Cytokinetics Inc (CYTK) director granted 272 fully vested shares - Stock Titan
Cytokinetics (NASDAQ: CYTK) director receives 151-share equity retainer grant - Stock Titan
Cytokinetics (NASDAQ: CYTK) awards director 151 fully vested shares - Stock Titan
All You Need to Know About Cytokinetics (CYTK) Rating Upgrade to Buy - Yahoo Finance Singapore
Wall Street Analysts Think Cytokinetics (CYTK) Could Surge 30.54%: Read This Before Placing a Bet - Yahoo Finance
Braveheart files for IPO to fund Phase 3 of Hengrui’s Cytokinetics rival - Endpoints News
US23282WAC4 Bond Profile — Key Metrics - TradingView
Cytokinetics president & CEO Robert Blum sells $615,149 of stock - Investing.com UK
FMR LLC Reduces Stake in Cytokinetics Inc: A Detailed Analysis - GuruFocus
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% - The Motley Fool
Cytokinetics president & CEO Robert Blum sells $615,149 of stock By Investing.com - Investing.com South Africa
What This Cytokinetics Insider Sale Might Mean With the Stock Up 110% - The Motley Fool
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cytokinetics Inc 주식 (CYTK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Callos Andrew | EVP, Chief Commercial Officer |
Jul 30 '26 |
Sale |
79.88 |
14,000 |
1,118,320 |
58,555 |
1.84%
0.91%
자본화:
|
볼륨(24시간):